Trial · NCT05092360

Phase 3 Study of Nemvaleukin Alfa in Combination With Pembrolizumab in Patients With Platinum-Resistant Epithelial Ovarian Cancer (ARTISTRY-7)

NCT05092360, Phase 3, Terminated, Mural Oncology, Inc; results first posted 2025-08-28

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Phase 3 Study of Nemvaleukin Alfa in Combination With Pembrolizumab in Patients With Platinum-Resistant Epithelial Ovarian Cancer (ARTISTRY-7). Trials, record NCT05092360. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05092360

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Phase 3 Study of Nemvaleukin Alfa in Combination With Pembrolizumab in Patients With Platinum-Resistant Epithelial Ovarian Cancer (ARTISTRY-7)
NCT number: NCT05092360
Status: Terminated
Phases: Phase 3
Enrollment: 456 participants, actual
Lead sponsor: Mural Oncology, Inc
Conditions: Platinum-resistant Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
Interventions: Nemvaleukin and Pembrolizumab Combination, Pembrolizumab, Nemvaleukin, Pegylated Liposomal Doxorubicin (PLD), Paclitaxel, Topotecan, Gemcitabine
First posted: 2021-10-25
Last updated: 2025-08-28
Results first posted: 2025-08-28
Limitations and caveats: Study was terminated due to business and strategic decision.

Source ClinicalTrials.gov

Registered outcomes8

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Overall Survival (OS)	From the first dose of study drug up to 24 months	Estimates based on Kaplan-Meier method.
Secondary	Objective Response Rate (ORR) as Assessed by Investigator	From the first dose of study drug up to 20 months	Response is based on RECIST v1.1 criteria.
Secondary	Disease Control Rate (DCR) as Assessed by Investigator	From the first dose of study drug up to 20 months	Response is based on RECIST v1.1 criteria.
Secondary	Duration of Response (DOR) as Assessed by Investigator	From the first dose of study drug up to 20 months	Response is based on RECIST v1.1 criteria.
Secondary	Time to Response (TTR) as Assessed by Investigator	From the first dose of study drug up to 20 months	Response is based on RECIST v1.1 criteria.
Secondary	Percentage of Participants With Cancer Antigen (CA)-125 Response as Defined by the Gynecologic Cancer Inter Group (GCIG)	From the first dose of study drug up to 20 months	A Cancer Antigen-125 response is defined as at least a 50% reduction in CA-125 levels from baseline, and the response must be confirmed and maintained for at least 28 days as per the GCIG.
Secondary	Number of Participants With Treatment-emergent Adverse Events (TEAEs)	From first dose of study drug up to 90 days after last dose (up to 23 months)
Secondary	Progression-free Survival (PFS) as Assessed by Investigator	From the first dose of study drug up to 20 months

Source ClinicalTrials.gov

Outcomes8

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Overall Survival (OS)	From the first dose of study drug up to 24 months	ITT population.	months	MEDIAN
SECONDARY	Objective Response Rate (ORR) as Assessed by Investigator	From the first dose of study drug up to 20 months	ITT population.	percentage of participants	NUMBER
SECONDARY	Disease Control Rate (DCR) as Assessed by Investigator	From the first dose of study drug up to 20 months	ITT population.	percentage of participants	NUMBER
SECONDARY	Duration of Response (DOR) as Assessed by Investigator	From the first dose of study drug up to 20 months	ITT population. Here N refers to number of participants with response and were analyzed for this outcome measure.	months	MEDIAN
SECONDARY	Time to Response (TTR) as Assessed by Investigator	From the first dose of study drug up to 20 months	ITT population. Here N refers to number of participants with response and were analyzed for this outcome measure.	months	MEDIAN
SECONDARY	Percentage of Participants With Cancer Antigen (CA)-125 Response as Defined by the Gynecologic Cancer Inter Group (GCIG)	From the first dose of study drug up to 20 months	ITT population.	percentage of participants	NUMBER
SECONDARY	Number of Participants With Treatment-emergent Adverse Events (TEAEs)	From first dose of study drug up to 90 days after last dose (up to 23 months)	Safety Set population.	Participants	COUNT_OF_PARTICIPANTS
SECONDARY	Progression-free Survival (PFS) as Assessed by Investigator	From the first dose of study drug up to 20 months	ITT population.	months	MEDIAN

Source ClinicalTrials.gov

Results by group28

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Value	Spread	Units
Overall Survival (OS)	Nemvaleukin 6 mcg/kg and Pembrolizumab 200 mg	10.1	95% Confidence Interval 7.4 to 12.5	months
Overall Survival (OS)	Pembrolizumab 200 mg	10.1	95% Confidence Interval 4.0 to NA	months
Overall Survival (OS)	Nemvaleukin 6 mcg/kg	10.7	95% Confidence Interval 8.1 to 13.9	months
Overall Survival (OS)	Investigator's Choice Chemotherapy	9.8	95% Confidence Interval 8.2 to 11.5	months
Objective Response Rate (ORR) as Assessed by Investigator	Nemvaleukin 6 mcg/kg and Pembrolizumab 200 mg	9.2	95% Confidence Interval 5.5 to 14.4	percentage of participants
Objective Response Rate (ORR) as Assessed by Investigator	Pembrolizumab 200 mg	0.0	95% Confidence Interval 0.0 to 6.5	percentage of participants
Objective Response Rate (ORR) as Assessed by Investigator	Nemvaleukin 6 mcg/kg	0.0	95% Confidence Interval 00 to 12.8	percentage of participants
Objective Response Rate (ORR) as Assessed by Investigator	Investigator's Choice Chemotherapy	11.1	95% Confidence Interval 7.0 to 16.4	percentage of participants
Disease Control Rate (DCR) as Assessed by Investigator	Nemvaleukin 6 mcg/kg and Pembrolizumab 200 mg	34.2	95% Confidence Interval 27.4 to 41.6	percentage of participants
Disease Control Rate (DCR) as Assessed by Investigator	Pembrolizumab 200 mg	25.9	95% Confidence Interval 11.1 to 46.3	percentage of participants

1 to 10 of 28Source ClinicalTrials.gov

See all 28 results by group

Participant flow20

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Nemvaleukin 6 mcg/kg and Pembrolizumab 200 mg	184
Overall Study	STARTED	Pembrolizumab 200 mg	27
Overall Study	STARTED	Nemvaleukin 6 mcg/kg	55
Overall Study	STARTED	Investigator's Choice Chemotherapy	190
Overall Study	Intent to Treat Population	Nemvaleukin 6 mcg/kg and Pembrolizumab 200 mg	184
Overall Study	Intent to Treat Population	Pembrolizumab 200 mg	27
Overall Study	Intent to Treat Population	Nemvaleukin 6 mcg/kg	55
Overall Study	Intent to Treat Population	Investigator's Choice Chemotherapy	190
Overall Study	Safety Set Population	Nemvaleukin 6 mcg/kg and Pembrolizumab 200 mg	178
Overall Study	Safety Set Population	Pembrolizumab 200 mg	26

1 to 10 of 20Source ClinicalTrials.gov

See all 20 participant flow

Adverse events708

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	Anaemia	Blood and lymphatic system disorders	Nemvaleukin 6 mcg/kg and Pembrolizumab 200 mg	53	184	102
other	Anaemia	Blood and lymphatic system disorders	Pembrolizumab 200 mg	3	27	3
other	Anaemia	Blood and lymphatic system disorders	Nemvaleukin 6 mcg/kg	15	55	31
other	Anaemia	Blood and lymphatic system disorders	Investigator's Choice Chemotherapy	64	190	165
other	Leukopenia	Blood and lymphatic system disorders	Nemvaleukin 6 mcg/kg and Pembrolizumab 200 mg	7	184	23
other	Leukopenia	Blood and lymphatic system disorders	Pembrolizumab 200 mg	1	27	1
other	Leukopenia	Blood and lymphatic system disorders	Nemvaleukin 6 mcg/kg	7	55	30
other	Leukopenia	Blood and lymphatic system disorders	Investigator's Choice Chemotherapy	10	190	38
other	Lymphopenia	Blood and lymphatic system disorders	Nemvaleukin 6 mcg/kg and Pembrolizumab 200 mg	27	184	60
other	Lymphopenia	Blood and lymphatic system disorders	Pembrolizumab 200 mg	0	27	0

1 to 10 of 708Source ClinicalTrials.gov

See all 708 adverse events

Adverse event totals12

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Nemvaleukin 6 mcg/kg and Pembrolizumab 200 mg	104	184
Total, all-cause mortality	Pembrolizumab 200 mg	15	27
Total, all-cause mortality	Nemvaleukin 6 mcg/kg	34	55
Total, all-cause mortality	Investigator's Choice Chemotherapy	105	190
Total, other adverse events	Nemvaleukin 6 mcg/kg and Pembrolizumab 200 mg	177	184
Total, other adverse events	Pembrolizumab 200 mg	23	27
Total, other adverse events	Nemvaleukin 6 mcg/kg	51	55
Total, other adverse events	Investigator's Choice Chemotherapy	171	190
Total, serious adverse events	Nemvaleukin 6 mcg/kg and Pembrolizumab 200 mg	74	184
Total, serious adverse events	Pembrolizumab 200 mg	8	27

1 to 10 of 12Source ClinicalTrials.gov

See all 12 adverse event totals

Papers1

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as
37334673	DERIVED

Source PubMed

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT05092360

GET https://conductscience.org/api/trials/v1/NCT05092360/results?page=2

API reference For AI assistants